Newsfeeds - Spark Newswire

Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Read More

9 minute read

Earnings

Earnings Scheduled For February 16, 2023

By Benzinga Insights

Today, 8:42 AM

Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year 2022.

Read More

1 minute read

Under Armour To Rally Over 13%? Here Are 5 Other Price Target Changes For Friday

Today, 8:42 AM

Telsey Advisory Group raised Under Armour, Inc.. (NASDAQ:UAA) price target from $8 to $9. Telsey Advisory Group analyst…

Read More

31 minute read

Earnings

Earnings Scheduled For November 3, 2022

By Benzinga Insights

Today, 8:42 AM

Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.

Read More

2 minute read

This Senator Just Bought Up To $100K In Artivion Stock

By Benzinga Insights

Today, 8:42 AM

The Office of Senator Tina Smith reported a purchase of Artivion (NYSE:AORT) stock on October 17, 2022. According to the October filing, the transaction was made on October 17, 2022.

Read More

30 minute read

Options

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

Today, 8:42 AM

During Wednesday's trading, 517 companies set new 52-week lows.

Read More

1 minute read

Morgan Stanley Maintains Equal-Weight on Artivion, Lowers Price Target to $14

By Benzinga Newsdesk

Today, 8:42 AM

Morgan Stanley analyst Cecilia Furlong maintains Artivion (NYSE:AORT) with a Equal-Weight and lowers the price target from $16 to $14.

Read More

23 minute read

Options

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 8:42 AM

On Friday, 404 stocks made new 52-week lows.

Read More

1 minute read

This Analyst Says Artivion’s Sell Off Seems Overdone After Trial Halt

By Vandana Singh

Today, 8:42 AM

On Friday, Artivion Inc (NYSE:AORT) stopped the PROACT Xa clinical trial after the Data Safety Monitoring Board (DSMB) indicated that…

Read More

1 minute read

Analyst Ratings

4 Analysts Have This to Say About Artivion

By Benzinga Insights

Today, 8:42 AM

Artivion (NYSE:AORT) has observed the following analyst ratings within the last quarter:

Read More

1 minute read

Oppenheimer Maintains Outperform on Artivion, Lowers Price Target to $25

By Benzinga Newsdesk

Today, 8:42 AM

Oppenheimer analyst Suraj Kalia maintains Artivion (NYSE:AORT) with a Outperform and lowers the price target from $35 to $25.